首页> 外国专利> SYNGR4 as a target gene for cancer therapy and diagnosis

SYNGR4 as a target gene for cancer therapy and diagnosis

机译:SYNGR4作为癌症治疗和诊断的靶基因

摘要

The present invention relates to the roles played by the SYNGR4 genes in lung cancer carcinogenesis and features a method for treating or preventing lung cancer by administering a double-stranded molecule against one or more of the SYNGR4 genes or a composition, vector or cell containing such a double stranded molecule and antibody. The present invention also features methods for diagnosing lung cancer or assessing/determining the prognosis of a patient with lung cancer, especially NSCLC or SCLC, using one or more over-expressed genes selected from among SYNGR4. To that end, SYNGR4 may serve as a novel serological biomarker for lung cancer. Also, disclosed are methods of identifying compounds for treating and preventing lung cancer, using as an index their effect on the over-expression of one or more of SYNGR4 in the lung cancer.
机译:本发明涉及SYNGR4基因在肺癌致癌中所起的作用,其特征在于通过给予针对一个或多个SYNGR4基因的双链分子或含有该基因的组合物,载体或细胞来治疗或预防肺癌的方法。双链分子和抗体。本发明的特征还在于使用选自SYNGR4中的一种或多种过表达的基因来诊断肺癌或评估/确定肺癌患者,尤其是NSCLC或SCLC的患者的预后的方法。为此,SYNGR4可以作为肺癌的新型血清生物标志物。还公开了鉴定化合物的方法,该化合物使用其对肺癌中一种或多种SYNGR4的过表达的影响作为指标来治疗和预防肺癌。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号